Shanghai Shen Lian Biomedical to acquire controlling stake in Yangzhou Zhiyuan

Shanghai Shen Lian Biomedical Corporation, through its wholly-owned subsidiary Shanghai Ben Tian Cheng Biomedical Co., Ltd., is investing RMB 60 million into Yangzhou Zhiyuan Bio-Technology Co., Ltd. Concurrently, the China Fuhui (Feidong) Investment Fund Partnership (Limited Partnership) is also investing RMB 60 million. Following these investments, both Shanghai Ben Tian Cheng and China Fuhui Fund will each hold 16.99% of Yangzhou Zhiyuan.

Shanghai Shen Lian Biomedical plans to acquire a controlling stake in Yangzhou Zhiyuan, making it a controlled subsidiary. This acquisition is outlined in a framework agreement, with the final equity proportion for Shanghai Shen Lian Biomedical and its concerted parties not less than 51%. The initial valuation for Yangzhou Zhiyuan’s 100% equity is estimated between RMB 360 million and RMB 500 million. The company concurrently announced that its 5% shareholder, United Biomedical, Inc., plans to divest up to 3% of its holdings to fund its own innovative drug development.

The company's Q3 2025 financial report shows a total revenue of RMB 237,694,760.86 and a net profit attributable to parent company shareholders of RMB 278,051.56 for the nine months ended September 30, 2025. This reflects a shift in operational strategy toward innovative drug development alongside its animal health business.